InnoCare Pharma Demonstrates Efficacy of Soficitinib in Phase 2 Trial for Vitiligo, Advancing to Phase 3
Topline Results from Soficitinib Phase 2 Trial Announced
InnoCare Pharma (HKEX: 09969) has announced the topline results from its Phase 2 trial of soficitinib (ICP-332), an oral TYK2 JH1 domain inhibitor, in patients with nonsegmental vitiligo. The 24-week trial demonstrated that the high-dose group achieved a 41.2% improvement in the Facial Vitiligo Area Scoring Index (F-VASI) compared to baseline, while the low-dose group showed a 38.8% improvement. These results represent a statistically significant improvement compared to the placebo group (2.2% improvement) and successfully met the primary endpoint. Based on this data, InnoCare Pharma will immediately proceed to the Phase 3 portion of its planned Phase 2/3 trial.
Unmet Need in the Vitiligo Market and the Advantage of Oral Administration
The global market for vitiligo, an autoimmune skin disease, is estimated at approximately $1.55 billion in 2025 and is projected to grow to over $2.24 billion in the early 2030s. Currently, the standard of care is Opzelura (ruxolitinib), a topical JAK inhibitor approved by Incyte (INCY) on July 18, 2022. However, topical application is limited for widespread or extensive lesions, highlighting the need for a convenient oral formulation. With soficitinib demonstrating significant F-VASI improvement as an oral agent, it has the potential to become a leading systemic oral alternative and transform the treatment paradigm for vitiligo.
Global TYK2 Inhibitor Competition and Differentiation Strategy
The global TYK2 market is currently led by Sotyktu (deucravacitinib) from Bristol Myers Squibb (BMS) and zasocitinib (TAK-279) from Takeda (TAK), which was acquired from Nimbus for approximately $4 billion in 2023. Notably, while Sotyktu and zasocitinib bind to the JH2 domain, soficitinib uniquely inhibits the JH1 domain, the catalytic activity site, through a distinct mechanism. In addition, InnoCare is advancing its internally developed TYK2 JH2 inhibitor, ICP-488, into Phase 3 trials for psoriasis and Phase 2 trials for lupus, aiming to secure a competitive advantage against large pharmaceutical companies.
R&D Advancement of a Chinese Biotech and Prospects for Global Technology Transfer
The achievement of global top-tier clinical data with soficitinib, developed on InnoCare Pharma's proprietary platform, demonstrates the overall R&D capabilities of the Chinese pharmaceutical and biotechnology industry. Following the successful Phase 3 trial for atopic dermatitis, the drug is simultaneously undergoing clinical development for various other skin conditions, including urticaria and psoriasis. The favorable safety and efficacy profile of soficitinib is expected to serve as a strong basis for establishing a large-scale global licensing partnership with Western pharmaceutical companies in the future.
InnoCare Pharma's soficitinib, an oral TYK2 JH1 inhibitor, has demonstrated clinical efficacy by improving F-VASI by up to 41.2% in a Phase 2 trial, overcoming the limitations of existing topical treatments. This represents an improvement over zasocitinib, which was acquired by Takeda (TAK) for approximately $4 billion, in a Phase 2 trial (NCT07108283), and positions it as a key driver in the vitiligo market, which is estimated at $1.55 billion in 2025, for systemic oral treatments. In the short term, the Phase 3 portion of the Phase 2/3 trial will be accelerated, expediting the timeline for commercialization. In the medium to long term, the synergy with the Phase 3 data for atopic dermatitis will maximize the value of the pipeline. Furthermore, the differentiated clinical data on the JH1 direct inhibition mechanism will create significant financial momentum by substantially increasing the valuation for a large-scale global licensing agreement with major pharmaceutical companies.